Ontology highlight
ABSTRACT: Background and objective
Altered levels of naturally occurring autoantibodies (nAbs) against disease-associated neuronal proteins have been reported for neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's disease (PD). Recent histopathologic studies suggest a contribution of both Lewy body- and AD-related pathology to Parkinson's disease dementia (PDD). Therefore, we explored nAbs against alpha-synuclein (?S), tau and ?-amyloid (A?) in PDD compared to cognitively normal PD patients.Materials and methods
We established three different ELISAs to quantify the nAbs-tau, nAbs-?S, and nAbs-A? levels and avidity towards their specific antigen in serum samples of 18 non-demented (PDND) and 18 demented PD patients (PDD), which were taken from an ongoing multi-center cohort study (DEMPARK/LANDSCAPE).Results
PDD patients had significantly decreased nAbs-tau serum levels compared to PDND patients (p = 0.007), whereas the serum titers of nAbs-?S and nAbs-A? were unchanged. For all three nAbs, no significant differences in avidity were found between PDD and PDND cohorts. However, within both patient groups, nAbs-tau showed lowest avidity to their antigen, followed by nAbs-?S, and nAbs-A?. Though, due to a high interassay coefficient of variability and the exclusion of many samples below the limit of detection, conclusions for nAbs-A? are only conditionally possible.Conclusion
We detected a significantly decreased nAbs-tau serum level in PDD patients, indicating a potential linkage between nAbs-tau serum titer and cognitive deficits in PD. Thus, further investigation in larger samples is justified to confirm our findings.
SUBMITTER: Kronimus Y
PROVIDER: S-EPMC5089716 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Kronimus Yannick Y Albus Alexandra A Balzer-Geldsetzer Monika M Straub Sarah S Semler Elisa E Otto Markus M Klotsche Jens J Dodel Richard R Mengel David D
PloS one 20161101 11
<h4>Background and objective</h4>Altered levels of naturally occurring autoantibodies (nAbs) against disease-associated neuronal proteins have been reported for neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's disease (PD). Recent histopathologic studies suggest a contribution of both Lewy body- and AD-related pathology to Parkinson's disease dementia (PDD). Therefore, we explored nAbs against alpha-synuclein (αS), tau and β-amyloid (Aβ) in PDD compared to cognitively normal ...[more]